HRP20202051T1 - Aril supstituirani pirimidini za uporabu kod infekcije virusom influence - Google Patents

Aril supstituirani pirimidini za uporabu kod infekcije virusom influence Download PDF

Info

Publication number
HRP20202051T1
HRP20202051T1 HRP20202051TT HRP20202051T HRP20202051T1 HR P20202051 T1 HRP20202051 T1 HR P20202051T1 HR P20202051T T HRP20202051T T HR P20202051TT HR P20202051 T HRP20202051 T HR P20202051T HR P20202051 T1 HRP20202051 T1 HR P20202051T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
polymorph
solvate
influenza virus
Prior art date
Application number
HRP20202051TT
Other languages
English (en)
Croatian (hr)
Inventor
Tim Hugo Maria Jonckers
David Craig Mc Gowan
JerĂ´me Emile Georges Guillemont
Werner Constant J. Embrechts
Guillaume Jean Maurice Mercey
Christophe Francis Robert Nestor Buyck
Wendy Mia Albert Balemans
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Company filed Critical Janssen Sciences Ireland Unlimited Company
Publication of HRP20202051T1 publication Critical patent/HRP20202051T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20202051TT 2016-01-20 2020-12-22 Aril supstituirani pirimidini za uporabu kod infekcije virusom influence HRP20202051T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16152095 2016-01-20
PCT/EP2017/051105 WO2017125506A1 (en) 2016-01-20 2017-01-19 Aryl substituted pyrimidines for use in influenza virus infection
EP17700580.8A EP3405466B1 (en) 2016-01-20 2017-01-19 Aryl substituted pyrimidines for use in influenza virus infection

Publications (1)

Publication Number Publication Date
HRP20202051T1 true HRP20202051T1 (hr) 2021-02-19

Family

ID=55345663

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20202051TT HRP20202051T1 (hr) 2016-01-20 2020-12-22 Aril supstituirani pirimidini za uporabu kod infekcije virusom influence

Country Status (20)

Country Link
US (2) US10611755B2 (ru)
EP (1) EP3405466B1 (ru)
JP (1) JP6989509B2 (ru)
KR (1) KR20180100375A (ru)
CN (1) CN108473477B (ru)
AU (1) AU2017209925B2 (ru)
BR (1) BR112018014794A2 (ru)
CA (1) CA3010327A1 (ru)
CL (1) CL2018001960A1 (ru)
CO (1) CO2018007669A2 (ru)
DK (1) DK3405466T3 (ru)
EA (1) EA201891666A1 (ru)
EC (1) ECSP18061667A (ru)
ES (1) ES2850575T3 (ru)
HR (1) HRP20202051T1 (ru)
HU (1) HUE053078T2 (ru)
LT (1) LT3405466T (ru)
MX (1) MX2018008803A (ru)
SI (1) SI3405466T1 (ru)
WO (1) WO2017125506A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20156325B (en) 2009-06-17 2015-07-10 Vertex Pharma Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3380467B1 (en) 2015-11-27 2021-07-07 Janssen Sciences Ireland Unlimited Company Heterocyclic indoles for use in influenza virus infection
MX2018008803A (es) * 2016-01-20 2018-11-09 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza.
CN107759571B (zh) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
AU2017376541B2 (en) 2016-12-15 2021-08-05 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532667A1 (en) 2005-09-30 2012-12-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
CN101641349A (zh) * 2007-02-08 2010-02-03 泰博特克药品有限公司 嘧啶取代的大环抑制剂
GEP20156325B (en) * 2009-06-17 2015-07-10 Vertex Pharma Inhibitors of influenza viruses replication
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
MX2013006836A (es) 2010-12-16 2013-09-26 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
EP2651938A1 (en) 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
BR122017025423B1 (pt) * 2011-04-08 2021-05-11 Janssen Sciences Ireland Uc derivados de pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2013184985A1 (en) * 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
LT2909195T (lt) * 2012-10-16 2017-09-25 Janssen Sciences Ireland Uc Antivirusiniai rsv junginiai
EA035174B1 (ru) * 2013-02-21 2020-05-12 Янссен Сайенсиз Айрлэнд Юси Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8
EP3380467B1 (en) 2015-11-27 2021-07-07 Janssen Sciences Ireland Unlimited Company Heterocyclic indoles for use in influenza virus infection
MX2018008803A (es) * 2016-01-20 2018-11-09 Janssen Sciences Ireland Uc Pirimidinas sustituidas con arilo para su uso en la infeccion por virus influenza.

Also Published As

Publication number Publication date
CL2018001960A1 (es) 2018-08-31
BR112018014794A2 (pt) 2018-12-11
EP3405466A1 (en) 2018-11-28
AU2017209925A1 (en) 2018-07-12
ES2850575T3 (es) 2021-08-30
WO2017125506A1 (en) 2017-07-27
JP6989509B2 (ja) 2022-01-05
EP3405466B1 (en) 2020-11-18
US10611755B2 (en) 2020-04-07
EA201891666A1 (ru) 2019-01-31
US20190047989A1 (en) 2019-02-14
SI3405466T1 (sl) 2021-02-26
ECSP18061667A (es) 2018-10-31
US20200231577A1 (en) 2020-07-23
JP2019507119A (ja) 2019-03-14
US11117887B2 (en) 2021-09-14
DK3405466T3 (da) 2021-02-01
MX2018008803A (es) 2018-11-09
HUE053078T2 (hu) 2021-06-28
CA3010327A1 (en) 2017-07-27
KR20180100375A (ko) 2018-09-10
CN108473477A (zh) 2018-08-31
CO2018007669A2 (es) 2018-08-10
LT3405466T (lt) 2021-01-25
CN108473477B (zh) 2021-10-22
AU2017209925B2 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
HRP20202051T1 (hr) Aril supstituirani pirimidini za uporabu kod infekcije virusom influence
HRP20210038T1 (hr) Pirolopirimidini za uporabu u infekciji virusom gripe
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
HRP20211223T1 (hr) Heterociklički indoli za upotrebu kod infekcije virusom influence
CY1121698T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
HRP20230274T1 (hr) Kemijski spojevi
HRP20200408T1 (hr) Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
HRP20171512T1 (hr) Derivati betulina
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
CL2017002022A1 (es) Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
JP2019510027A5 (ru)
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
JP2016508134A5 (ru)
TR201908994T4 (tr) Farmasötik bileşimler.
HRP20201645T1 (hr) Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
HRP20201187T1 (hr) Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR104504A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
TH182826B (th) สารประกอบไทรแอซีนและการใช้สารนั้นเพื่อวัตถุประสงค์ทางการแพทย์